Orthocell Ltd OCC

Orthocell Ltd (ASX:OCC, OTC:ORHHF) managing director and CEO Paul Anderson spoke with Proactive's Stephen Gunnion about the company recording its first Remplir sales in Thailand, expanding the global commercial footprint of its nerve repair product. Anderson said the milestone forms part of Orthocell's strategy to continually expand its international presence, with Remplir now generating revenue across seven markets including the US, Australia, New Zealand, Singapore, Hong Kong and Thailand. "We're really excited about first sales in Thailand," he said, describing the country as significant fr

Orthocell Ltd (ASX:OCC, OTC:ORHHF) has recorded the first commercial sales of its Remplir™ nerve repair product in Thailand, extending the regenerative medicine company’s Asian footprint and opening another revenue-generating market for the product. The first sales follow Thai FDA approval...

Orthocell Ltd (ASX:OCC, OTC:ORHHF) earlier this week reported record quarterly and full-year revenue as accelerating adoption of its Remplir™ nerve repair device strengthened the company’s commercial growth outlook. Revenue reached A$3.8 million in the June quarter, up 20% from the March...

Orthocell Ltd CEO and managing director Paul Anderson talked with Proactive about the company’s record quarterly and full-year revenue, accelerating adoption of its Remplir™ nerve repair device and the outlook for further commercial growth in Australia, the United States and other international markets. Orthocell reported revenue of A$3.8 million for the June quarter, representing a 20% increase from the March quarter and a 36% rise compared with the corresponding period last year. FY2026 revenue increased by 44% to a record A$13.2 million, supported by growing sales of Remplir and Striate+™ a

Orthocell Ltd (ASX:OCC, OTC:ORHHF) has posted record quarterly and full-year revenue, with accelerating adoption of its Remplir™ nerve repair device in Australia and the United States strengthening the regenerative medicine company’s commercial growth outlook. Revenue reached A$3.8 million in...

The S&P/ASX Small Ordinaries Index finished Friday at 3,392.70 points, gaining 23.50 points, or 0.70%, for the session. Despite the positive finish, the index remained 48.80 points, or 1.42%, lower over the past five trading days. Several ASX-listed small caps delivered operational...

Orthocell Ltd (ASX:OCC, OTC:ORHHF) has appointed MediTime as the exclusive in-country distributor for its nerve repair product Remplir™ in Thailand, opening a commercial pathway into a Thai nerve repair market estimated at about US$84 million. The appointment follows regulatory approval from...

The S&P/ASX Small Ordinaries Index (ASX) edged higher, adding 10.70 points, or 0.31%, to 3,407.70 yesterday. Despite the daily lift, the index remains lower over the past five sessions, down 26.30 points, or 0.77%, to 3,406.10, reflecting a still-cautious tone across the small-cap...

Orthocell Ltd (ASX:OCC, OTC:ORHHF) has expanded the humanitarian rollout of its nerve repair device, Remplir™, in Ukraine, following growing use of the product for severe peripheral nerve injuries caused by the ongoing conflict. The regenerative medicine company said additional devices were...

Orthocell Ltd (ASX:OCC, OTC:ORHHF) earlier this week said Remplir™ had moved beyond market access and into active clinical use within the US military and veteran healthcare system, marking an important step in the company’s commercial expansion strategy. Managing director Paul Anderson told...

Orthocell Ltd (ASX:OCC, OTC:ORHHF) has reported a solid March 2026 quarter, highlighted by $3.2 million in revenue, growing US traction for nerve repair product Remplir and a cash position of $48 million as the company advances commercial expansion across multiple markets. Revenue for the...

US benchmark WTI crude fell nearly 11% after Iran’s foreign minister signaled that the Strait of Hormuz would remain open

Orthocell Ltd (ASX:OCC, OTC:ORHHF) will release its quarterly results for the period ended March 31, 2026, on Monday, April 20, and host an investor webinar the same day. The webinar will cover its quarterly results and provide an operational update, including progress on the US rollout of...